NASDAQ$TERN
Terns Pharmaceuticals Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Terns Pharmaceuticals reported financial results for Q2 2021 and corporate highlights.
Terns Pharmaceuticals reported a net loss of $10.7 million for the second quarter ended June 30, 2021. As of June 30, 2021, cash, cash equivalents and marketable securities were $185.1 million. Top-line data from the TERN-501 Phase 1 trial is expected in 4Q 2021, and data from Part 1 of the TERN-201 AVIATION Trial is expected in 1H 2022.
- Initiated Phase 1b AVIATION Trial of TERN-201 and the multiple ascending dose (MAD) cohort of TERN-501 Phase 1 trial.
- Reported positive top-line data from Phase 2a LIFT Study of TERN-101.
- TERN-501 received Fast Track Designation from the U.S. FDA in June 2021.
- Cash and equivalents of $185.1 million provides runway into 2024.
Headline financials
Revenue & EPS history
Terns · Revenue · Quarterly
$0
Forward guidance
Terns expects to report top-line data from ongoing Phase 1 proof of concept clinical trial of TERN-501 in 4Q 2021 and top-line data readout from Part 1 of ongoing AVIATION Trial of TERN-201 in 1H 2022. The company expects that current funds will be sufficient to support its planned operating expenses into 2024.
Tailwinds
- Top-line data from ongoing Phase 1 proof of concept clinical trial of TERN-501 expected in 4Q 2021
- Top-line data readout from Part 1 of ongoing AVIATION Trial of TERN-201 expected in 1H 2022
- Cash and equivalents of $185.1 million provides runway into 2024
- TERN-501: Thyroid hormone receptor-beta (THR-β) agonist initiated 14-day multiple ascending dose (MAD) portion of Phase 1 trial in June 2021
- TERN-201: Vascular adhesion protein-1 (VAP-1) inhibitor initiated 12-week Phase 1b AVIATION Trial in NASH in June 2021
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
-0.3%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+16.4%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+19.8%
Q4 2022
Best reaction
-23.0%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.3% | -0.0% | — | |
| Q3 2025 | +7.6% | +18.0% | +146.3% | |
| Q2 2025 | -6.8% | +3.6% | +18.7% | |
| Q1 2025 | -0.7% | -4.1% | +22.3% | |
| Q4 2024 | -2.7% | -1.3% | -23.6% | |
| Q3 2024 | -9.1% | -17.3% | -11.7% | |
| Q2 2024 | -4.6% | -11.8% | -1.7% | |
| Q1 2024 | +7.7% | +6.1% | +32.9% | |
| Q4 2023 | +1.7% | -15.0% | -27.4% | |
| Q3 2023 | +14.2% | +10.1% | +92.3% | |
| Q2 2023 | -9.5% | +0.8% | -21.5% | |
| Q1 2023 | -15.2% | -20.3% | -7.0% | |
| Q4 2022 | +19.8% | +32.7% | +42.3% | |
| Q3 2022 | -23.0% | -26.7% | -12.2% | |
| Q2 2022 | -5.5% | +39.2% | +75.1% | |
| Q1 2022 | +4.0% | -0.7% | +26.5% | |
| Q4 2021 | +4.1% | +3.5% | -5.4% | |
| Q3 2021 | -1.2% | -5.9% | -30.9% | |
| Q2 2021 | +4.3% | +3.5% | -0.9% | |
| Q1 2021 | +3.6% | +5.6% | +13.5% | |
| Q4 2020 | +5.8% | -0.9% | +1.2% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro